Pieris Pharmaceuticals Stock Price on May 8, 2024
| PIRS Stock | USD 16.84 0.07 0.42% |
Below is the normalized historical share price chart for Pieris Pharmaceuticals extending back to December 26, 2014. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of Pieris Pharmaceuticals stands at 16.84, as last reported on the 25th of November, with the highest price reaching 17.00 and the lowest price hitting 15.85 during the day.
If you're considering investing in Pieris Stock, it is important to understand the factors that can impact its price. Pieris Pharmaceuticals maintains Sharpe Ratio (i.e., Efficiency) of -0.0294, which implies the firm had a -0.0294% return per unit of risk over the last 3 months. Pieris Pharmaceuticals exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check Pieris Pharmaceuticals' Variance of 5.1, coefficient of variation of (1,953), and Risk Adjusted Performance of (0.03) to confirm the risk estimate we provide.
At this time, Pieris Pharmaceuticals' Total Stockholder Equity is comparatively stable compared to the past year. Sale Purchase Of Stock is likely to gain to about 71.4 M in 2024, whereas Common Stock Shares Outstanding is likely to drop slightly above 674 K in 2024. . Price Earnings To Growth Ratio is likely to gain to 0.02 in 2024, whereas Price To Sales Ratio is likely to drop 0.36 in 2024. Pieris Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 13th of April 2015 | 200 Day MA 13.7876 | 50 Day MA 16.5766 | Beta 0.662 |
Pieris |
Sharpe Ratio = -0.0294
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | PIRS |
Estimated Market Risk
| 2.24 actual daily | 19 81% of assets are more volatile |
Expected Return
| -0.07 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.03 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Pieris Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Pieris Pharmaceuticals by adding Pieris Pharmaceuticals to a well-diversified portfolio.
Price Book 1.3614 | Enterprise Value Ebitda (1.47) | Price Sales 1.0611 | Shares Float 808.1 K | Wall Street Target Price 7 |
Related Headline
Inozyme Pharma Headline on 8th of May 2024
Inozyme Pharma to Participate at the Bank of America Securit... by finance.yahoo.com
BOSTON, May 08, 2024 -- Inozyme Pharma, Inc. , a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced Doug Treco, Ph.D., CEO and Chairman of Inozyme, will participate in a fireside chat at the Bank of America Securities 2024 Health Care Conference on Wednesday, May 15, 2024 from 640-710pm ET 340-410pm PT. A live
Pieris Pharmaceuticals Valuation on May 8, 2024
It is possible to determine the worth of Pieris Pharmaceuticals on a given historical date. On May 8, 2024 Pieris was worth 10.9 at the beginning of the trading date compared to the closed value of 11.14. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of Pieris Pharmaceuticals stock. Still, in general, we apply an absolute valuation method to find Pieris Pharmaceuticals' value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of Pieris Pharmaceuticals where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against Pieris Pharmaceuticals' related companies.
| Open | High | Low | Close | Volume | |
| 10.99 | 11.18 | 10.87 | 11.04 | 10,745 | |
05/08/2024 | 10.90 | 11.25 | 10.90 | 11.14 | 8,944 |
| 11.32 | 11.32 | 11.16 | 11.16 | 2,146 |
| Backtest Pieris Pharmaceuticals | | | Pieris Pharmaceuticals History | | | Pieris Pharmaceuticals Valuation | Previous | Next |
Pieris Pharmaceuticals Trading Date Momentum on May 8, 2024
| On May 09 2024 Pieris Pharmaceuticals was traded for 11.16 at the closing time. The top price for the day was 11.32 and the lowest listed price was 11.16 . The trading volume for the day was 2.1 K. The trading history from May 9, 2024 was a factor to the next trading day price appreciation. The trading delta at closing time against the next closing price was 0.18% . The trading delta at closing time against the current closing price is 1.26% . |
Pieris Pharmaceuticals Fundamentals Correlations and Trends
By evaluating Pieris Pharmaceuticals' financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among Pieris Pharmaceuticals' main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. Pieris financial account trend analysis is a perfect complement when working with valuation or volatility modules.About Pieris Pharmaceuticals Stock history
Pieris Pharmaceuticals investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Pieris is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Pieris Pharmaceuticals will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Pieris Pharmaceuticals stock prices may prove useful in developing a viable investing in Pieris Pharmaceuticals
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 1.1 M | 674 K | |
| Net Loss | -41.2 M | -39.1 M |
Pieris Pharmaceuticals Quarterly Net Working Capital |
|
Pieris Pharmaceuticals Stock Technical Analysis
Pieris Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Price Boundaries
Pieris Pharmaceuticals Period Price Range
Low | November 25, 2024
| High |
0.00 | 0.00 |
Pieris Pharmaceuticals cannot be verified against its exchange. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
Pieris Pharmaceuticals November 25, 2024 Market Strength
Market strength indicators help investors to evaluate how Pieris Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Pieris Pharmaceuticals shares will generate the highest return on investment. By undertsting and applying Pieris Pharmaceuticals stock market strength indicators, traders can identify Pieris Pharmaceuticals entry and exit signals to maximize returns
Pieris Pharmaceuticals Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Pieris Pharmaceuticals' price direction in advance. Along with the technical and fundamental analysis of Pieris Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Pieris to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | (0.03) | |||
| Jensen Alpha | (0.20) | |||
| Total Risk Alpha | (0.48) | |||
| Treynor Ratio | (0.21) |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Additional Tools for Pieris Stock Analysis
When running Pieris Pharmaceuticals' price analysis, check to measure Pieris Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pieris Pharmaceuticals is operating at the current time. Most of Pieris Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Pieris Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pieris Pharmaceuticals' price. Additionally, you may evaluate how the addition of Pieris Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.